**Aotearoa New Zealand Tall Man lettering list**

List updated October 2023

A PDF version is available on the Te Tāhū Hauora Health Quality & Safety Commission website: [www.hqsc.govt.nz/resources/resource-library/aotearoa-new-zealand-tall-man-lettering-list](https://www.hqsc.govt.nz/resources/resource-library/aotearoa-new-zealand-tall-man-lettering-list)

| **Medicine** | **Medicine class** | **Year** |
| --- | --- | --- |
| aFATinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| aLEMTUzumab | Monoclonal antibodies ('mabs') | 2020 |
| ALKeran | Medicines used predominantly in cancer therapy | 2013 |
| aLLOPURINol | General | 2013 |
| amINOPHYLLIne | General | 2013 |
| amIODAROne | General | 2013 |
| amiSULPRIDe | General | 2013 |
| amITRIPTYLIne | General | 2013 |
| amLODIPIne | General | 2013 |
| aPomine | General | 2013 |
| arATAC | General | 2013 |
| arOPAX | General | 2013 |
| aTENOLol | General | 2013 |
| aTEZOLIzumab | Monoclonal antibodies ('mabs') | 2020 |
| aTRopt | General | 2013 |
| avaSTIN | Medicines used predominantly in cancer therapy | 2013 |
| avaXIM | Medicines used predominantly in cancer therapy | 2013 |
| aVomine | General | 2013 |
| aXITinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| azATHIOPRINE | General | 2013 |
| azITHROMYCIN | General | 2013 |
| aZopt | General | 2013 |
| BENZATHINE benzylpenicillin | General | 2013 |
| benzylpenicillin\* | General | 2013 |
| beVACizumab | Monoclonal antibodies ('mabs') | 2020 |
| bisACODYl | General | 2013 |
| bisOPROLOl | General | 2013 |
| buDESONide | General | 2013 |
| buMETANide | General | 2013 |
| buPROPION | General | 2020 |
| buSPIRONE | General | 2020 |
| caLTRate | General | 2013 |
| caPTOPRIl | General | 2013 |
| caRAFate | General | 2013 |
| CARBAMazepine | General | 2013 |
| carbIMAZOLe | General | 2013 |
| cARBOplatin | Medicines used predominantly in cancer therapy | 2013 |
| caRVEDILOl | General | 2013 |
| cefaCLOR | cephalosporins | 2020 |
| cefaLEXin | Cephalosporins | 2013 |
| cefaZOLin | Cephalosporins | 2013 |
| cefEPIME | Cephalosporins | 2013 |
| cefOTAXIME | Cephalosporins | 2013 |
| cefOXITIN | Cephalosporins | 2013 |
| ceftAROLine | cephalosporins | 2020 |
| cefTAZIDIME | Cephalosporins | 2013 |
| cefTRIAXONE | Cephalosporins | 2013 |
| cefUROXIME | Cephalosporins | 2013 |
| celAPRAM | General | 2013 |
| celEBREX | General | 2013 |
| cephaLEXin | Cephalosporins | 2013 |
| cephaZOLin | Cephalosporins | 2013 |
| CETUximab | Medicines used predominantly in cancer therapy | 2013 |
| cHLORPROMAZIne | General | 2013 |
| ciclosPORIN | General | 2020 |
| ciprAMIL | General | 2013 |
| cIPROFLOXAcin | General | 2013 |
| ciprOXIN | General | 2013 |
| cISplatin | Medicines used predominantly in cancer therapy | 2013 |
| cLARITHROMYcin | General | 2013 |
| clINDAmycin | General | 2013 |
| clobazam\* | General | 2020 |
| cLOMIFEne | General | 2020 |
| cLOMIPRAMIne | General | 2013 |
| CLONazepam | Benzodiazepines | 2013 |
| cloNIDine | General | 2013 |
| cLOZAPine | General | 2013 |
| cOBIMEtinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| coUMADIN | General | 2013 |
| coVERSYL | General | 2013 |
| cyclIZINE | Medicines used predominantly in cancer therapy | 2013 |
| cyclOBLASTIN | Medicines used predominantly in cancer therapy | 2013 |
| CYCLOPHOSPHamide | Medicines used predominantly in cancer therapy | 2013 |
| cyclosERINE | General | 2013 |
| cyclosPORIN | General | 2013 |
| daBRAFEnib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| daCTINomycin | Medicines used predominantly in cancer therapy | 2013 |
| daPTomycin | Medicines used predominantly in cancer therapy | 2013 |
| daSATinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| DAUNOrubicin | Medicines used predominantly in cancer therapy | 2013 |
| DEPO-medrol | General | 2013 |
| depo-PROVERA | General | 2013 |
| DIazepam | Benzodiazepines | 2013 |
| dIGOXin | General | 2013 |
| diPYRIDAMOLe | General | 2013 |
| diSOPYRAMIDe | General | 2013 |
| doBUTamine | General | 2020 |
| DOCEtaxel | Medicines used predominantly in cancer therapy | 2013 |
| doPamine | General | 2020 |
| doTHIEpin | General | 2013 |
| dOXAZOSin | General | 2013 |
| doXEpin | General | 2013 |
| DOXOrubicin | Medicines used predominantly in cancer therapy | 2013 |
| DULoxetine | SSRI/SNRI | 2013 |
| ERYthromycin | General | 2013 |
| fluoxetine\* | SSRI/SNRI | 2013 |
| fluARIx | General | 2013 |
| flupENTIXOL | General | 2020 |
| flupHENAZINE | General | 2013 |
| fluVAx | General | 2013 |
| fluVOXAMine | SSRI/SNRI | 2013 |
| folic acid\* | General | 2013 |
| foliNIc acid | General | 2013 |
| gliBENCLAMide | Sulphonylurea agents | 2013 |
| gliCLAZide | Sulphonylurea agents | 2013 |
| gliPIZide | Sulphonylurea agents | 2013 |
| humALOG | General | 2013 |
| humULIN | General | 2013 |
| hyoscine BUTYLbromide | General | 2013 |
| hyoscine HYDRObromide | General | 2013 |
| IDArubicin | Medicines used predominantly in cancer therapy | 2013 |
| IFOSFamide | Medicines used predominantly in cancer therapy | 2013 |
| imipramine\* | General | 2013 |
| imUPRine | General | 2013 |
| INDEral | General | 2013 |
| INFLIximab | Medicines used predominantly in cancer therapy | 2013 |
| isopto CARpine | General | 2013 |
| isopto HOMATROpine | General | 2013 |
| ISOtretinoin | General | 2013 |
| januMET | General | 2013 |
| januVIA | General | 2013 |
| ketALAR | General | 2013 |
| ketOROLAC | General | 2013 |
| laMICTAl | General | 2013 |
| laMISIl | General | 2013 |
| lamIVUDine | General | 2013 |
| lamOTRIGine | General | 2013 |
| lanTUs | General | 2013 |
| lanVIs | General | 2013 |
| laPAtinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| laRGACTIl | General | 2013 |
| LEUKeran | Medicines used predominantly in cancer therapy | 2013 |
| LORazepam | Benzodiazepines | 2013 |
| loxaLATe | General | 2013 |
| loxaMINe | General | 2013 |
| maxiDEX | General | 2013 |
| maxiTROL | General | 2013 |
| meDROXYPROGESTERone | General | 2013 |
| m-eNALAPRIL | General | 2013 |
| mercaptAMine (cysteamine) | General | 2020 |
| mercaptOPURine | General | 2020 |
| m-eSLON | General | 2013 |
| methADONe | General | 2013 |
| metHOTREXATe | General | 2013 |
| methYLPHENIDATe | General | 2013 |
| methylprednisolone ACETate | General | 2013 |
| methylprednisolone SODIUM SUCCINate | General | 2013 |
| metOCLOPRAMIDe | General | 2013 |
| metoPROLOL | General | 2013 |
| MOXIfloxacin | General | 2013 |
| MYLeran | Medicines used predominantly in cancer therapy | 2013 |
| nalOXone | General | 2020 |
| nalTREXone | General | 2020 |
| neO-MERCAZOLe | General | 2013 |
| NEOral | General | 2013 |
| neUROKARe | General | 2013 |
| niFEDIPine | General | 2013 |
| niMODIPine | General | 2013 |
| NITRazepam | Benzodiazepines | 2013 |
| NORfloxacin | General | 2013 |
| norMISON | General | 2013 |
| norVASC | General | 2013 |
| novoMIX | General | 2013 |
| novoRAPID | General | 2013 |
| novoSEVEN | General | 2013 |
| oBINUTUZumab | Monoclonal antibodies ('mabs') | 2020 |
| oMALizumab | Monoclonal antibodies ('mabs') | 2020 |
| OXazepam | Benzodiazepines | 2013 |
| OXCARBazepine | General | 2013 |
| oxyCONTIN | General | 2013 |
| oxyNORM | General | 2013 |
| PACLItaxel | Medicines used predominantly in cancer therapy | 2013 |
| PARoxetine | SSRI/SNRI | 2013 |
| pAZOPanib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| pegFILGRASTIM | General | 2013 |
| pegINTERFERON | General | 2013 |
| penicillAMINE | General | 2013 |
| pERTUZumab | Monoclonal antibodies ('mabs') | 2020 |
| prEDNISone | General | 2013 |
| primaCIN | General | 2013 |
| primaCOR | General | 2013 |
| primAQUIne | General | 2013 |
| primaXIN | General | 2013 |
| primIDOne | General | 2013 |
| proCHLORPERazine | General | 2013 |
| procYCLIDine | General | 2013 |
| proGRAF | General | 2013 |
| proMETHazine | General | 2013 |
| propOFol | General | 2013 |
| propRANOLol | General | 2013 |
| proZAC | General | 2013 |
| QUETIAPine | General | 2013 |
| quINine | General | 2013 |
| rifaMPICin | General | 2020 |
| rifaXIMin | General | 2020 |
| riSPERIDONe | General | 2020 |
| RITUximab | Medicines used predominantly in cancer therapy | 2013 |
| rOPINIROLe | General | 2020 |
| SERTRALine | General | 2013 |
| SIrolimus | General | 2013 |
| siTagliptin | General | 2020 |
| solu-CORTEF | General | 2013 |
| SOLU-medrol | General | 2013 |
| soRAFENib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| sulfaDIazine | General | 2013 |
| sulfaSALazine | General | 2013 |
| sUMATRIPTAn | General | 2020 |
| sUNITinib | Tyrosine kinase inhibitors ('nibs') | 2020 |
| TACrolimus | General | 2013 |
| TAMoxifen | General | 2020 |
| tEMOdal | General | 2013 |
| toFRANIL | General | 2013 |
| toPAMAX | General | 2013 |
| tRAMadol | General | 2013 |
| tretinoin\* | General | 2013 |
| trimEPRAZINE | General | 2013 |
| trimETHOPRIM | General | 2013 |
| valAciclovir | General | 2013 |
| valGANciclovir | General | 2013 |
| vinBLASTine | Medicines used predominantly in cancer therapy | 2013 |
| vinCRISTine | Medicines used predominantly in cancer therapy | 2013 |
| vinORELBine | Medicines used predominantly in cancer therapy | 2013 |
| yasMIN | General | 2020 |
| yaZ | General | 2020 |
|  |  |  |
| \* Not capitalised as part of the Tall Man lettering methodology exception rules list published December 2013. | | |